Physician profile
Robert Cohen
NPI 1538131719
$3,917.96
in general payments reported to CMS, 2019-2025
28 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $49.50 · 2022: $1,012 · 2023: $1,169 · 2024: $1,242 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,549.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $581.59 | 2019-2024 | Skyrizi |
| Genzyme Corporation | $415.88 | 2022-2024 | |
| Janssen Biotech, INC. | $366.13 | 2022-2024 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $314.24 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $307.36 | 2022-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $199.71 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $182.43 | 2022-2024 | Ilumya, Winlevi, Absorica Ld |
| Incyte Corporation | $144.45 | 2022-2024 | Opzelura |
| Janssen Scientific Affairs, LLC | $125.68 | 2022 | |
| Amgen INC. | $119.64 | 2024 | Otezla |
| Leo Pharma INC. | $107.00 | 2022-2024 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $99.99 | 2019 | |
| Lilly USA, LLC | $94.57 | 2022-2024 | Taltz, Olumiant |
| Otsuka America Pharmaceutical, INC. | $89.24 | 2024-2025 | Rexulti |
| Arcutis Biotherapeutics, INC. | $86.06 | 2023-2024 | Zoryve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $84.43 | 2023-2024 | Bimzelx, Cimzia |
| Lundbeck LLC | $84.33 | 2023-2025 | Rexulti |
| Verrica Pharmaceuticals INC. | $82.89 | 2023-2024 | Ycanth |
| Galderma Laboratories, L.P. | $79.34 | 2022-2024 | Oracea |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.34 | 2023 | Cyltezo |
| Regeneron Healthcare Solutions, INC. | $63.63 | 2020-2022 | |
| Smith+Nephew, INC. | $58.79 | 2022 | |
| Dermavant Sciences, INC. | $56.56 | 2022-2023 | Vtama |
| Sanofi-Aventis U.S. LLC | $23.01 | 2025 | |
| Biofrontera INC. | $21.83 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Genentech USA, INC. | $19.36 | 2019 | |
| Merz Pharmaceuticals, LLC | $17.51 | 2025 | Inbrija |
| Allergan, INC. | $13.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.